PACLITAXEL
Generic: PACLITAXEL
BluePoint LaboratoriesManufacturer
INTRAVENOUSRoute
PACLITAXELActive Substance
2020-08-24Original Approval
PACLITAXEL is FDA application ANDA213434, sponsored by MSN. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2012-06-27
Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for HospiraThe affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and
Class III2013-11-08
PACLITAXEL INJECTION, USP (semisynthetic); 300 mg/50 mL; (6 mg/mL); Multiple Dose Vial;(NDC 63323-763-50); Rx Only; ManLabeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical S
Top Reported Reactions
1
NAUSEA
4,740 reports
2
DYSPNOEA
4,687 reports
3
NEUTROPENIA
4,634 reports
4
OFF LABEL USE
4,561 reports
5
DIARRHOEA
4,390 reports
6
ANAEMIA
4,038 reports
7
MALIGNANT NEOPLASM PROGRESSION
3,944 reports
8
MYELOSUPPRESSION
3,679 reports
9
DISEASE PROGRESSION
3,482 reports
10
FATIGUE
3,481 reports